FOXO1 and cerebral cavernous malformation: Consistent with previous results [28,79,80], here we show that IL-Mix has a therapeutic effect on the expression levels of most KRIT1-loss-dependent biomarkers underlying the pathogenesis of CCM disease, with the best results in the FoxO1/SOD2 pathway where a complete reversion of the phenotype is achieved.